Quantifying Optimal Relugolix Duration with Radiation in High Risk Prostate Cancer
Androgen deprivation therapy (ADT) is an essential treatment for high-risk prostate cancer along with radiation; however there are significant side effects. A return to normal testosterone levels after ADT can take months to years, meaning these side effects persist after treatment. A novel form of ADT, Relugolix, shows rapid testosterone recovery after treatment. However, this may mean patients must continue treatment longer to be effective. We will study the effect of 12 months and 24 months of Relugolix combined with high dose radiation (through both brachytherapy and external beam radiation) in patients with high-risk prostate cancer. This will be a randomized clinical trial with 90 patients and three years of follow-up. We will look at genomic information to determine if that informs who needs longer Relugolix treatment. Our results may help physicians and patients understand how to maximize the chance of cures with Relugolix while balancing quality of life.
